Safety data sheet
Standardized safety protocols and material specifications for professional use.
Certificate of Analysis
Purity verified via High-Performance Liquid Chromatography (HPLC) for #myo-tirzepatide-60mg
Tirzepatide (60mg)
Ultra High >99.5% Purity
Authorized Resellers
Available through our trusted partners
123peptide.com
Netherlands · Europe
local_shipping2-3 Business Days
Depeptidenwinkel.com
Netherlands · Europe
local_shipping2-3 Business Days
Scientific Background
Looking for the ultimate convenience for long-term or high-dose protocols? This 60mg vial delivers exceptional value and minimizes reconstitution frequency while providing the same powerful dual GLP-1/GIP action that makes tirzepatide so effective.
Tirzepatide is a synthetic 39-amino-acid peptide that functions as a dual agonist for GLP-1 and GIP receptors. It mimics natural incretin hormones, leading to glucose-dependent insulin release, glucagon suppression, delayed gastric emptying, and strong central appetite regulation.
This size is ideal for dedicated users pursuing extended protocols. Enjoy consistent appetite suppression, enhanced metabolic efficiency, and impressive body composition improvements over extended periods.
Intended Research Use
- Substantial and sustained body weight reduction
- Powerful HbA1c and fasting glucose improvements
- Appetite suppression and enhanced satiety
- Improved lipid profile and cardiometabolic markers
- Reduced visceral and liver fat content
menu_bookScientific Publications
N Engl J Med (2022)
Tirzepatide once weekly for the treatment of obesity
open_in_newhttps://pubmed.ncbi.nlm.nih.gov/35658024/
N Engl J Med (2021)
Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes
open_in_newhttps://pubmed.ncbi.nlm.nih.gov/34170647/
Lancet (2021)
Once-weekly tirzepatide versus once-daily insulin degludec (SURPASS-3)
open_in_newhttps://pubmed.ncbi.nlm.nih.gov/34370921/
JAMA (2022)
Effect of subcutaneous tirzepatide vs placebo on glycemic control (SURPASS-5)
open_in_newhttps://pubmed.ncbi.nlm.nih.gov/35133415/
Maximum Value: The 60mg vial provides the best value per mg for long-term protocols. Reconstituted at ~20 mg/mL, it allows very small injection volumes and can last multiple months at maintenance dosing.
FOR RESEARCH USE ONLY. This product is intended for laboratory research purposes only and is not for human consumption, medical, or diagnostic use.
Possible stacks with other peptides
Synergistic combinations for enhanced research outcomes
Clinical research suggests combining Tirzepatide with complementary peptides can enhance weight management and metabolic outcomes.
Cagrilintide (5mg vial)
arrow_forwardmyo-cagrilintide-5mg
Adds amylin-like satiety enhancement for even greater appetite control.
Tesamorelin (10mg vial)
arrow_forwardmyo-tesamorelin-10mg
Targets visceral fat reduction via GH stimulation.
AOD-9604 (5mg vial)
arrow_forwardmyo-hgh-fragment-aod-9604-5mg
Direct lipolytic action complements tirzepatide's incretin-driven fat metabolism.
MOTS-c (10mg vial)
arrow_forwardmyo-mots-c-10mg
Mitochondrial optimization supports energy levels during caloric deficit.
Semaglutide 5mg (5mg vial)
arrow_forwardmyo-semaglutide-5mg
Comparable GLP-1 agonist for appetite suppression — studied alongside Tirzepatide for weight loss protocol comparison and sequential research designs.
Retatrutide 10mg (10mg vial)
arrow_forwardmyo-retatrutide-10mg
Triple GLP-1/GIP/glucagon agonist with reported fat reduction up to 24% — investigated as an advanced alternative to Tirzepatide's dual mechanism.
CagriSema (Semaglutide + Cagrilintide) (5mg + 5mg vial)
arrow_forwardmyo-semaglutide-plus-cagrilintide-5mg-5mg
GLP-1 plus amylin dual-action blend offering complementary satiety mechanisms alongside Tirzepatide's incretin pathway for enhanced weight management research.
Cycling Note: Once-weekly subcutaneous injection for 12–26+ weeks.
